Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
15 September 2014 - Gilead Sciences has announced agreements with a handful of Indian pharmaceutical manufacturers to produce and sell generic versions of two new hepatitis C drugs – sofosbuvir and ledipasvir. Approximately 180 million people live with hepatitis C today, with 350,000 people dying annually of the disease.
Last updated 15 September 2014
MSF joins civil society and many other groups in asking Janssen to reduce the price of their new TB medicine, bedaquiline, which is the first new TB drug to receive approval in 40 years. The drug is currently approved to treat patients with the deadliest form of drug-resistant tuberculosis, XDR-TB, but the current pricing structure is prohibitive, particularly for middle-income countries. Read the letter below.
Last updated 12 September 2014
Background: On 27 August 2014, the European Commission (EC) and the European Medicines Agency (EMA) became the second stringent regulatory authority (after Japan in July) to approve new direct-acting antiviral (DAA) daclatasvir, used to treat hepatitis C. Daclatasvir is the third DAA - a new class of oral drugs used to treat hepatitis C – to be approved.
Last updated 27 August 2014
MSF Letter to Indian government - IP negotiations in the Regional Comprehensive Economic Partnership
Ahead of the RCEP Ministerial Conference to be held in Myanmar on 27-28 August 2014, see letter from Medecins Sans Frontieres addressed to the Indian Minister of State for Commerce & Industry regarding the inclusion of intellectual property (IP) in the negotiations of the Regional Comprehensive Economic Partnership (RCEP) and its potential impact on access to affordable generic medicines from India.
Médecins Sans Frontières (MSF) expresses our condolences to the families, friends, and colleagues of those onboard the Malaysian Airlines flight MH17 that crashed in Ukraine yesterday. MSF is deeply saddened and shocked at the loss of many people from the HIV community - leading scientists, researchers, activists and allies among them - who were heading for the 2014 International AIDS Conference in Melbourne. The HIV community will feel their loss profoundly; we can only honour them by re-doubling our commitment and efforts to address the HIV pandemic.
Last updated 18 July 2014
Following this morning's launch of UNAIDS' Gap report on the state of the HIV epidemic, including access to antiretroviral therapy (ART), Médecins Sans Frontières (MSF) responds to the news that at the end of 2013, nearly 13 million people living with HIV were on ART, including almost 12 million in the developing world, an increase of more than 20% from the end of 2012.
Last updated 16 July 2014
MSF statement in conjunction with the sixth BRICS Summit, being held in Fortaleza and Brasília, Brazil, from 14-16 July, 2014.
Last updated 15 July 2014
Seventy six groups have co-signed MSF's letter urging the GAVI Alliance to support a hepatitis B virus (HBV) birth dose vaccination. Hepatitis B affects more than 240 million people globally, causing over 600,000 deaths each year. The highest burden of HBV infection lies in low- and middle-income countries, but only 18 of 56 GAVI-eligible countries are currently delivering the HBV birth dose. Please click below to read our letter to the GAVI Alliance.
Last updated 18 June 2014
67th WHO World Health Assembly – Agenda item 15.4 Access to Essential Medicines, Resolution EB 134.R16 Speaker: Helle Aagaard, EU Policy and Advocacy Advisor, MSF Access Campaign MSF programmes stand witness to the fact that medicines affordability is still a critical problem. For many new medicines addressing public health challenges, from communicable diseases like HIV, tuberculosis and HCV, to NCDs like cancer, high prices keep medical tools out of the reach of MSF, patients and governments.
Last updated 23 May 2014
MSF intervention on the report of the Consultative Expert Working Group on Research and Development at 67th World Health Assembly
World Health Assembly 67 – Agenda item 15.2 Speaker: Katy Athersuch, Medical Innovation & Access Policy Adviser, Médecins Sans Frontières International